COYA 302
Amyotrophic Lateral Sclerosis (ALS)
Key Facts
About Coya Therapeutics
Coya Therapeutics is pioneering a novel approach to treating chronic inflammatory diseases by targeting and enhancing the function of regulatory T cells (Tregs). The company has generated strong proof-of-concept data in Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, with its lead biologic candidate, COYA 302, advancing in clinical trials for ALS and Frontotemporal Dementia (FTD). As a public, clinical-stage biotech, Coya is leveraging its multi-modality Treg platform to address significant unmet needs in large neurodegenerative and autoimmune markets.
View full company profileAbout Coya Therapeutics
Coya Therapeutics is pioneering a novel approach to treating chronic inflammatory diseases by targeting and enhancing the function of regulatory T cells (Tregs). The company has generated strong proof-of-concept data in Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, with its lead biologic candidate, COYA 302, advancing in clinical trials for ALS and Frontotemporal Dementia (FTD). As a public, clinical-stage biotech, Coya is leveraging its multi-modality Treg platform to address significant unmet needs in large neurodegenerative and autoimmune markets.
View full company profileTherapeutic Areas
Other Amyotrophic Lateral Sclerosis (ALS) Drugs
| Drug | Company | Phase |
|---|---|---|
| Utreloxastat (PTC857) | PTC Therapeutics | Phase 2 |
| SAR443820/DNL788 | Denali Therapeutics | Phase 2 |
| Pegcetacoplan | Apellis Pharmaceuticals | Phase 2 |
| RELYVRIO/ALBRIOZA (AMX0035) | Amylyx Pharmaceuticals | Approved/Commercial |
| AMX0035 | Amylyx Pharmaceuticals | Phase 3 |
| AMX0114 | Amylyx Pharmaceuticals | Phase 1 |
| Taldefgrobep alfa | Biohaven | Phase 2/3 |
| AMT-162 | uniQure | Preclinical |
| AAV-UPF1 | MeiraGTx | Preclinical |
| Tegoprubart | Eledon Pharmaceuticals | Phase 2 |
| Intranasal Foralumab | Tiziana Life Sciences | Phase 2 |
| TDP-43 Program | Korro Bio | Discovery |